Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
September 5, 2018
Vericel (VCEL) gains as former competitor Histogenicss (HSGX) fails to meet endpoints
August 17, 2018
Gene editing stocks, time to harvest some upside?
August 16, 2018
RegMed Investors’ (RMi): call me crazy if I had all the answers but, I have more than most …
August 8, 2018
REGENXBIO (RGNX) proposes a $175 M offering
July 25, 2018
bluebird bio (BLUE) prices 3.348 M share offering at $162.50
July 24, 2018
CRSPR stocks stay in the tank in another session…
July 23, 2018
Neuralstem (CUR) presents pre-clinical data that NSI-189 Improves cognition and anxiety
July 23, 2018
CRSPR stocks stay in the tank …
July 23, 2018
Alnylam (ALNY) Clinical Results from APOLLO P3 Study of Patisiran
July 23, 2018
Applied Genetic Technologies (AGTC) 1st patient of 2nd cohort in P1/2 clinical XLRP study
July 2, 2018
MiMedx Group (MDXG) a BIG broom sweeps all...
July 2, 2018
Mesoblast (MESO) $50 M debt deal, with a stock purchase, a re-payment plan from net sales
July 2, 2018
BioLife Solutions (BLFS) reports Q2/18 – Blow-Out
June 19, 2018
Caladrius Biosciences (CLBS) receives FDA’s RMAT designation for CD34+ for treating Refractory Angina
June 18, 2018
Solid Biosciences (SLDB) clinical hold removed on SGT-001 DMD (Duchenne muscular dystrophy) treatment
June 7, 2018
MiMedx Group (MDXG) crashes after news of a 5 year restatement and CFO departs
April 23, 2018
Pluristem (PSTI) and Indiana University evaluating PLX-R18 in Acute Radiation Syndrome (ARS)
April 16, 2018
Organovo (ONVO) Achieves liver disease and intestinal 3D bio-printed tissue models milestones - BUY
April 12, 2018
Organovo Holdings (ONVO) presents data on creating drug profile of chronic liver disease progression - BUY
April 10, 2018
Caladrius Biosciences (CLBS) receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for treating CLI - BUY
April 9, 2018
Cesca Therapeutics (KOOL) proposes a $10 M unit and attached warrant offering in new prospectus
April 9, 2018
Regenxbio (RGNX) license with AveXis (AVXS) on Novartis (NVS) acquisition news triggers $180 M pay-day
April 3, 2018
Cellectis (CLLS) and Allogene Therapeutics accelerate allogeneic off-the-shelf CAR T Therapies
March 28, 2018
bluebird bio (BLUE)and Celgene (CELG) ink agreement to co-develop/promote Anti-BCMA CAR T cell therapy (bb2121) in the US
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.